With the current data on combinations of antiangiogenic agents and immunotherapy or ICI-ICI therapy, the panel members believe that high-dose IL2 no longer plays a role in the management of advanced RCC (consensus; LE: 1b; GR: B) due to the low rate of complete response and high risk of severe toxicity (Fyfe et al. 1995). Here, IL2 is linked to renal cell carcinoma.